Finance

Beta
Lists
CANF:NYSEAMERICAN
Can Fite Biopharma ADR Representing 300 Ord Shs
$3.16
0.00%
(0.00) 1D
Jun 4, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CANF...
Mkt. cap
19.88M
Avg. vol.
995.51K
Volume
133.00
52-wk high
$23.40
52-wk low
$2.83
Beta
1.12
Shares outstanding
2.14M
No. of employees
5
Mkt. cap
19.88M
Avg. vol.
995.51K
Volume
133.00
52-wk high
$23.40
52-wk low
$2.83
Beta
1.12
Shares outstanding
2.14M
No. of employees
5
Analyst outlook
Analyst Ratings
Based on 2 analysts giving stock ratings to CANF in the past 3 months
Buy
Buy
2
Hold
0
Sell
0
12 month forecast
Based on 2 Wall Street analysts offering 12 month price targets for CANF in the last 3 months.
Highest
Current $3.16
$7.00 (+121.52%)
Average
$6.00 (+89.87%)
Lowest
$5.00 (+58.23%)
News stories
From sources across the web
About Can Fite Biopharma ADR Representing 300 Ord Shs
CEO-
Employees5
Founded1994
Headquarters-
SectorBiotechnology
Websitecanfite.com
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Revenue
101.00K
101.00K
101.50K
101.50K
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
1.52M
1.52M
1.83M
1.83M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1.03M
1.03M
798.00K
798.00K
Operating expense
2.55M
2.55M
2.63M
2.63M
Total operating expenses
2.55M
2.55M
2.63M
2.63M
Operating income
-2.45M
-2.45M
-2.53M
-2.53M
Other non operating income
-
-
-7.00K
-7.00K
EBT including unusual items
-2.44M
-2.44M
-2.48M
-2.48M
EBT excluding unusual items
-2.44M
-2.44M
-2.47M
-2.47M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-2.44M
-2.44M
-2.48M
-2.48M
Net profit margin
-2,413.86%
-2,413.86%
-2,439.41%
-2,439.41%
Earnings per share
-
-
-
-
Interest and investment income
11.00K
11.00K
131.00K
131.00K
Interest expense
-
-
-
-
Net interest expenses
11.00K
11.00K
131.00K
131.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-2.44M
-2.44M
-2.53M
-2.53M
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer